| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S00259-009-1349-9 |
| P698 | PubMed publication ID | 20107793 |
| P50 | author | Valentina Ambrosini | Q37842637 |
| Davide Campana | Q45862458 | ||
| P2093 | author name string | Paolo Castellucci | |
| Cristina Nanni | |||
| Maurizio Zompatori | |||
| Domenico Rubello | |||
| Paola Tomassetti | |||
| Giancarlo Montini | |||
| Stefano Fanti | |||
| Roberto Franchi | |||
| Vincenzo Allegri | |||
| P2860 | cites work | Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours | Q24685837 |
| The Measurement of Observer Agreement for Categorical Data | Q26778373 | ||
| Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy. | Q33484071 | ||
| Recent advances in radiological and radionuclide imaging and therapy of neuroendocrine tumours. | Q35833855 | ||
| Nuclear imaging of neuroendocrine tumours | Q36768664 | ||
| 68Ga-DOTANOC: biodistribution and dosimetry in patients affected by neuroendocrine tumors | Q40173504 | ||
| Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? | Q40182879 | ||
| DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals | Q44561169 | ||
| Imaging of advanced neuroendocrine tumors with (18)F-FDOPA PET. | Q44964622 | ||
| Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours | Q45126334 | ||
| Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival | Q45192171 | ||
| 68Ga-DOTA-NOC: a new PET tracer for evaluating patients with bronchial carcinoid | Q46107039 | ||
| Imaging of neuroendocrine tumors: accuracy of helical CT versus SRS. | Q47431676 | ||
| Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours | Q48159200 | ||
| Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours. | Q51571439 | ||
| Neuroendocrine tumour of the mediastinum: fusion of 18F-FDG and 68Ga-DOTATOC PET/CT datasets demonstrates different degrees of differentiation. | Q53502873 | ||
| Can fluorodihydroxyphenylalanine PET replace somatostatin receptor scintigraphy in patients with digestive endocrine tumors? | Q53521560 | ||
| 68Ga-DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5. | Q53603570 | ||
| 68Ga-DOTA-Tyr3-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT | Q57757715 | ||
| Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization | Q57820372 | ||
| Processing of generator-produced 68Ga for medical application. | Q64947317 | ||
| P433 | issue | 4 | |
| P1104 | number of pages | 6 | |
| P304 | page(s) | 722-727 | |
| P577 | publication date | 2010-01-27 | |
| P1433 | published in | European Journal of Nuclear Medicine and Molecular Imaging | Q15708890 |
| P1476 | title | (68)Ga-DOTA-NOC PET/CT in comparison with CT for the detection of bone metastasis in patients with neuroendocrine tumours. | |
| P478 | volume | 37 |
| Q53191850 | Are contrast media required for (68)Ga-DOTATOC PET/CT in patients with neuroendocrine tumours of the abdomen? |
| Q89996366 | Bone Metastases in Neuroendocrine Neoplasms: From Pathogenesis to Clinical Management |
| Q44647880 | Clinical value of a combined multi-phase contrast enhanced DOPA-PET/CT in neuroendocrine tumours with emphasis on the diagnostic CT component. |
| Q30476277 | Current molecular imaging of spinal tumors in clinical practice |
| Q24603675 | ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes |
| Q37990395 | Gallium-labelled peptides for imaging of inflammation |
| Q40014600 | Gastro-entero-pancreatic neuroendocrine tumors: Is now time for a new approach? |
| Q48089118 | Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F-DOPA. |
| Q37986065 | Imaging with non-FDG PET tracers: outlook for current clinical applications |
| Q46152235 | Is ⁶⁸Ga-DOTA-NOC PET/CT indicated in patients with clinical, biochemical or radiological suspicion of neuroendocrine tumour? |
| Q56619661 | MEDICINAL RADIOPHARMACEUTICAL CHEMISTRY OF METAL RADIOPHARMACEUTICALS |
| Q90164675 | Nuclear Imaging of Neuroendocrine Tumors |
| Q38027393 | Nuclear medicine in NET. |
| Q37888852 | Orthopaedic research in italy: state of the art. |
| Q59074896 | PET and PET/CT with 68gallium-labeled somatostatin analogues in Non GEP-NETs Tumors |
| Q26992201 | PET tracers for somatostatin receptor imaging of neuroendocrine tumors: current status and review of the literature |
| Q42993036 | Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE. |
| Q37435222 | Prospective of ⁶⁸Ga-radiopharmaceutical development |
| Q26996521 | Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids |
| Q40455264 | Somatostatin receptor positron emission tomography/computed tomography imaging in Merkel cell carcinoma. |
| Q48206758 | Surgical Resection for Pulmonary Carcinoid: Long-Term Results of Multicentric Study-The Importance of Pathological N Status, More Than We Thought |
| Q50103017 | The Evolution of Neuroendocrine Tumor Treatment reflected by ENETS Guidelines |
| Q52980637 | The added value of 68Ga-DOTA-TATE-PET to contrast-enhanced CT for primary site detection in CUP of neuroendocrine origin. |
| Q47731752 | The utility of 68Ga-DOTATATE positron-emission tomography/computed tomography in the diagnosis, management, follow-up and prognosis of neuroendocrine tumors |
| Q57640099 | Vertebral metastases from neuroendocrine tumours: How to avoid false positives on Ga-DOTA-TOC PET using CT pattern analysis? |
Warning: Trying to access array offset on value of type null in /home/httpd/vhosts/renenyffenegger.ch/opendata.renenyffenegger.ch/Wikimedia/Wikidata/entity/main.php on line 1120 Warning: Trying to access array offset on value of type null in /home/httpd/vhosts/renenyffenegger.ch/opendata.renenyffenegger.ch/Wikimedia/Wikidata/entity/main.php on line 1120
Search more.